trial
as of 2026-07-01Cognitive Therapy for Negative Symptoms and Functioning
NCTId NCT00350883
at a glance
Phase 2 · Completed
Enrollment 61 (actual)
Sponsored by University of Pennsylvania
Primary completion 2011-11
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
61 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2006-07
Primary completion
2011-11
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
University of PennsylvaniaLead Sponsor
Investigators
2
Aaron T Beck, MDPrincipal Investigator
Paul M Grant, PhDStudy Director
Sites
1 total
Philadelphia, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
61
Phase
PHASE2
Primary Completion Date
2011-11
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
collaborator
indication
investigator
person
person